

Special Issue

New Advances in Haemostasis, Thrombosis and Angiology

Message from the Guest Editor

Venous thromboembolism remains a leading cause of morbidity and mortality worldwide and a crucial global health concern. In recent decades, scientific advances in the understanding of the pathophysiology of hemostasis and thrombosis, as well as the introduction of new pharmacological agents for the prevention and treatment of venous thromboembolism, have revolutionized the biomedical and clinical landscape.

In the near future, individualized approaches to venous thromboembolism risk stratification, prophylaxis, and treatment will allow us to significantly improve patient care.

The aim of this Special Issue is to provide an overview of exciting new research in the areas of hemostasis, thrombosis, and angiology, paving the way for personalized approaches to the management of venous thromboembolism.

We are soliciting basic, original, translational, and clinical papers, especially focusing on diagnostic and prognostic biomarkers as well as novel drug targets or targeted treatments, including clinical trials.

Guest Editor

Dr. Corinne Frere

INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition, GRC 27 GRECO, Sorbonne Université, F-75013 Paris, France

Deadline for manuscript submissions

closed (10 August 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/92405

*Journal of Personalized
Medicine*

Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://jpm.mdpi.com)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).